Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 35/100

Failure Rate

0.0%

0 terminated/withdrawn out of 5 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

50%

2 of 4 completed trials have results

Key Signals

2 with results

Enrollment Performance

Analytics

Phase 2
3(100.0%)
3Total
Phase 2(3)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (5)

Showing 5 of 5 trials
NCT02461459Active Not Recruiting

Autism Spectrum Disorder (ASD) and Intellectual Disability (ID) Determinants in Tuberous Sclerosis Complex (TSC)

Role: collaborator

NCT00126672Phase 2Completed

RAPAMYCIN FOR KIDNEY ANGIOMYOLIPOMAS

Role: collaborator

NCT01780441Completed

Early Biomarkers of Autism in Infants With Tuberous Sclerosis Complex (TSC)

Role: collaborator

NCT01289912Phase 2Completed

Trial of RAD001 and Neurocognition in Tuberous Sclerosis Complex (TSC)

Role: collaborator

NCT00457808Phase 2Completed

Rapamycin Therapy for Patients With Tuberous Sclerosis Complex and Sporadic LAM

Role: collaborator

All 5 trials loaded